Stevens Capital Management LP Bei Gene, Ltd. Transaction History

Stevens Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 21, 2020	SELL	$121.84 - $173.19 $226,866 - $322,479	-1,862 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$115.78 - $208.34 $215,582 - $387,929	1,862 New	1,862 $309,000
Q2 2019 Jul 31, 2019	SELL	$113.99 - $146.86 $301,161 - $388,004	-2,642 Closed	0 $0
Q1 2019 May 03, 2019	BUY	$122.82 - $151.83 $324,490 - $401,134	2,642 New	2,642 $349,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Stevens Capital Management LP with notifications on news.